US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

0.2779

-0.1121-28.74%

Post-market: 0.2505-0.0274-9.86%19:59 EST

Volume:1.90M

Turnover:563.42K

Market Cap:3.71M

PE:-0.06

High:0.3495

Open:0.3401

Low:0.2570

Close:0.3900

52wk High:11.00

52wk Low:0.0002

Shares:13.36M

Float Shares:3.40M

Volume Ratio:1.55

T/O Rate:55.93%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.9510

EPS(LYR):-14.8490

ROE:-1236.83%

ROA:-427.27%

PB:0.26

PE(LYR):-0.02

Loading ...

Overview Company News Filings

Propanc Biopharma files new provisional patent application with IP Australia

Propanc Biopharma Develops Synthetic Enzyme Therapy for Metastatic Cancer

Propanc Biopharma Advances PRP Candidate Toward Human Trials for Pancreatic Cancer

Propanc Biopharma issues letter to shareholders

Propanc Biopharma Reaffirms Focus on Long-Term Growth Amid Share Price Volatility

Propanc Biopharma Announces 2026 Strategy to Advance PRP Clinical Development, Expand Into New Therapeutic Areas, and Progress Synthetic Backup Compound Rec-PRP

Propanc Biopharma Provides Shareholder Update

THOMSON REUTERS

Propanc Biopharma Faces Nasdaq Delisting Risk Over Minimum Bid Price

BRIEF-Propanc Biopharma Files Prospectus For Resale Of 2 Million Shares By Selling Stockholder - SEC Filing

Propanc Biopharma Inc - Files Prospectus for Resale of 2 Mln Shares by Selling Stockholder - SEC Filing

THOMSON REUTERS

Propanc Biopharma Inc. Files Information Statement Detailing Authorized Corporate Actions

Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts

Propanc Biopharma Files Draft Information Statement Outlining Authorized Corporate Actions

Propanc Biopharma Targets Cancer and Fibrosis With Novel PRP Therapy

Propanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment

Propanc Biopharma Q1 2025 EPS $(0.39) Up From $(35.97) YoY

BRIEF-Propanc Biopharma Provides Corporate Update And Reports First Quarter 2025/26 Results

Propanc Biopharma Reports Nasdaq Uplisting and $4 Million Public Offering

Propanc Biopharma Inc Qtrly EPS $-0.39

THOMSON REUTERS

Propanc Biopharma Secures Up to $100 Million in Private Placement from Hexstone Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PPCB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.2779,"timestamp":1769720400000,"preClose":0.39,"halted":0,"volume":1904289,"hourTrading":{"tag":"盘后","latestPrice":0.2505,"preClose":0.2779,"latestTime":"19:59 EST","volume":123190,"amount":31755.5139,"timestamp":1769734795667,"change":-0.0274,"changeRate":-0.098597,"amplitude":0.116589},"delay":0,"changeRate":-0.28743589743589754,"floatShares":3404500,"shares":13364244,"eps":-4.951,"marketStatus":"Not Yet Opened","change":-0.1121,"latestTime":"01-29 16:00:00 EST","open":0.3401,"high":0.3495,"low":0.257,"amount":563416.6544208,"amplitude":0.237179,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.951,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769763600000},"marketStatusCode":0,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.39,"preHourTrading":{"tag":"盘前","latestPrice":0.3489,"preClose":0.39,"latestTime":"09:29 EST","volume":68711,"amount":24573.277775069997,"timestamp":1769696984994,"change":-0.0411,"changeRate":-0.105385,"amplitude":0.163333},"postHourTrading":{"tag":"盘后","latestPrice":0.2505,"preClose":0.2779,"latestTime":"19:59 EST","volume":123190,"amount":31755.5139,"timestamp":1769734795667,"change":-0.0274,"changeRate":-0.098597,"amplitude":0.116589},"volumeRatio":1.549502},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":3404500,"roa":"-427.27%","roe":"-1236.83%","lyrEps":-14.848963,"volumeRatio":1.549502,"shares":13364244,"dividePrice":0,"high":0.3495,"amplitude":0.237179,"preClose":0.39,"low":0.257,"week52Low":0.0002,"pbRate":"0.26","week52High":11,"institutionHeld":0,"latestPrice":0.2779,"eps":-4.951,"divideRate":0,"volume":1904289,"delay":0,"ttmEps":-4.951,"open":0.3401,"prevYearClose":0.536601,"prevWeekClose":0.28,"prevMonthClose":0.5366,"prevQuarterClose":0.5366,"fiveDayClose":0.266,"twentyDayClose":0.58,"sixtyDayClose":1.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-01-28","current":-0.05613,"percent":0.931034,"low":-1.336323,"twenty":-0.450277,"median":-0.230387,"eighty":-0.123469,"high":-0.048332,"avg":-0.307582,"sd":0.228511,"marketCap":3971853},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-28","current":-0.062641,"twenty":-0.450277,"median":-0.230387,"eighty":-0.123469,"marketCap":3971853}],"updateTime":1769750369308},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2604116209","title":"Propanc Biopharma files new provisional patent application with IP Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116209?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:56","pubTimestamp":1768917418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that a new provisional patent application has been filed for methods of producing trypinsogen and chymotrypsinog...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-files-new-provisional-patent-application-with-ip-australia-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-files-new-provisional-patent-application-with-ip-australia-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1487256676.USD","LU1169589451.USD","BK4585","BK4136","BK4588","LU1481600234.SGD","PPCB","LU2463526074.USD","LU1481599808.USD","LU1169590202.USD","BK4139","IP","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2604116191","title":"Propanc Biopharma Develops Synthetic Enzyme Therapy for Metastatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116191","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116191?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:45","pubTimestamp":1768916713,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. announced the filing of a new provisional patent application for methods of producing trypsinogen and chymotrypsinogen, utilizing an optimized expression system to create a fully synthetic recombinant version of PRP, aimed at treating and preventing metastatic cancer from solid tumors. The company highlights that this synthetic approach could offer significant advantages, including longer shelf life without refrigeration and consistent quality without relying on animal sources. These developments are part of Propanc's ongoing efforts to expand its intellectual property portfolio and develop novel cancer therapies. The announcement pertains to the patent filing and does not specify the presentation of scientific research results at this time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDLT7tkQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","BK4585","BK4588","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","PPCB","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2603198330","title":"Propanc Biopharma Advances PRP Candidate Toward Human Trials for Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603198330","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603198330?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:45","pubTimestamp":1768484708,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. announced an update on its pancreatic cancer research, highlighting progress with its pancreatic proenzyme formulation, PRP. The company has not yet presented clinical research results but is advancing plans to initiate Phase I/II human clinical trials in 2026. These upcoming studies will begin with dose-finding and move to proof-of-concept trials for pancreatic and other cancers. Propanc emphasizes the scientific rationale behind PRP while acknowledging significant challenges in demonstrating clinical benefit in pancreatic cancer. The company remains in early-stage development and has not reported product revenues to date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the origin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL3WSSjw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","LU2210149790.SGD","PPCB","LU0314104364.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2603879326","title":"Propanc Biopharma issues letter to shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2603879326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603879326?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:56","pubTimestamp":1768312571,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced a shareholder update from its Chief Executive Officer and Cofounder, James Nathanielsz. “I am delighted to share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-issues-letter-to-shareholders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-issues-letter-to-shareholders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2603682708","title":"Propanc Biopharma Reaffirms Focus on Long-Term Growth Amid Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682708?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:45","pubTimestamp":1768311920,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. issued a shareholder update addressing recent enquiries about the company's share price performance following its Nasdaq listing. CEO James Nathanielsz emphasized that short-term market dynamics can affect share prices, but the company remains committed to its long-term strategy and clinical development goals. The update highlighted progress in preparing for a Phase 1b clinical trial of the lead asset, PRP, at the Peter MacCallum Cancer Centre, with activities such as manufacturing and bioanalytical validation underway. The company reassured shareholders of its focus on value creation and ongoing scientific and clinical achievements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL9bMBQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","PPCB","BK4585","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","BK4588","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4139","LU0314104364.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2603827056","title":"Propanc Biopharma Announces 2026 Strategy to Advance PRP Clinical Development, Expand Into New Therapeutic Areas, and Progress Synthetic Backup Compound Rec-PRP","url":"https://stock-news.laohu8.com/highlight/detail?id=2603827056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603827056?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:45","pubTimestamp":1768311910,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Announces 2026 Strategy to Advance PRP Clinical Development, Expand Into New Therapeutic Areas, and Progress Synthetic Backup Compound Rec-PRP. Propanc Biopharma Inc. announced its strategic plans for 2026, focusing on the continued clinical development of its lead asset, PRP, and the expansion of its scientific platform into additional therapeutic areas with high unmet medical need. The company is also advancing its pipeline with the development of a fully synthetic backup compound, Rec-PRP. Propanc intends to further strengthen its intellectual property portfolio, with three new patent applications entering the national phase in multiple jurisdictions. Ongoing research collaborations with the Universities of Jaén and Granada are expected to support these initiatives. The company aims to create long-term value through these activities and maintain regular communication with shareholders as progress is made.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL7Kvf27:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","PPCB","LU0314104364.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","SG9999014021.USD","NDAQ","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2603682780","title":"Propanc Biopharma Provides Shareholder Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682780?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:45","pubTimestamp":1768311900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA5HDPZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2601381710","title":"Propanc Biopharma Faces Nasdaq Delisting Risk Over Minimum Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2601381710","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601381710?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:01","pubTimestamp":1767823284,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550. While this notice does not result in immediate delisting, the company faces the risk of its stock being removed from the Nasdaq Capital Market if it fails to regain compliance. Potential delisting could negatively affect the liquidity and market price of Propanc's common stock, reduce investor interest, hinder the company's ability to raise capital, and impair its capacity to offer equity incentives to employees. Propanc is monitoring its stock price and considering options to address the issue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL21XcV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2595285799","title":"BRIEF-Propanc Biopharma Files Prospectus For Resale Of 2 Million Shares By Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595285799","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595285799?lang=en_us&edition=fundamental","pubTime":"2025-12-30 19:06","pubTimestamp":1767092771,"startTime":"0","endTime":"0","summary":"BRIEF-Propanc Biopharma Files Prospectus For Resale Of 2 Million Shares By Selling Stockholder - SEC FilingDec 30  - Propanc Biopharma Inc PPCB.O:PROPANC BIOPHARMA INC - FILES PROSPECTUS FOR RESALE OF 2 MILLION SHARES BY SELLING STOCKHOLDER - SEC FILINGSource text: [ID:n0001493152-25-029472]Further company coverage: PPCB.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3XZ07F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2595779945","title":"Propanc Biopharma Inc - Files Prospectus for Resale of 2 Mln Shares by Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595779945","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595779945?lang=en_us&edition=fundamental","pubTime":"2025-12-30 19:04","pubTimestamp":1767092688,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3XZ07F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2595558397","title":"Propanc Biopharma Inc. Files Information Statement Detailing Authorized Corporate Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=2595558397","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595558397?lang=en_us&edition=fundamental","pubTime":"2025-12-30 06:14","pubTimestamp":1767046465,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. has announced that its shareholders have approved key corporate actions related to a private placement agreement with Hexstone Capital LLC. Authorized on October 7, 2025, the agreement involves the issuance of Series C Preferred Stock, with each share convertible into common stock. This development marks an important step for the company as it seeks to advance its strategic initiatives. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLbqVGWt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2593548400","title":"Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2593548400","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593548400?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:02","pubTimestamp":1766404925,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma  fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL9J1sMQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014021.USD","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4139","LU2210150020.SGD","SG9999014039.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","PPCB","IE00BKPKM429.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590556361","title":"Propanc Biopharma Files Draft Information Statement Outlining Authorized Corporate Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=2590556361","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590556361?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:24","pubTimestamp":1765405482,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. announced that its shareholders have authorized corporate actions related to a private placement agreement. On October 7, 2025, the company entered into a Securities Purchase Agreement with Hexstone Capital LLC for the private placement of Series C Preferred Stock. Each share of Series C Preferred Stock will be convertible into shares of common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL7trqTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2588873878","title":"Propanc Biopharma Targets Cancer and Fibrosis With Novel PRP Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588873878","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588873878?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:45","pubTimestamp":1764855911,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. has announced plans to investigate the phenomenon of \"mesenchymal drift\" as part of its ongoing research into novel treatments for chronic diseases, including recurrent and metastatic cancer. The company is focusing on how its lead product candidate, PRP-a combination of pancreatic proenzymes trypsinogen and chymotrypsinogen-may impact epithelial-to-mesenchymal transition  pathways, which are central to both cancer progression and fibrosis. Propanc is preparing to begin a Phase 1b First-In-Human study of PRP in patients with advanced solid tumors in 2026, with further Phase 2 trials planned. The scientific results are part of an expanding research program and have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL7ZwrXx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4112","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","LU2095319765.USD","NDAQ","PPCB","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2588739107","title":"Propanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588739107","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588739107?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:03","pubTimestamp":1764597835,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. has announced the submission of a request for a foreign filing license from Spain for two provisional patents describing new methods to treat resistant cancer and fibrosis. These discoveries, resulting from a joint research and drug discovery program with the Universities of Jaén and Granada in Spain, will be filed with IP Australia and are expected to be submitted in key global jurisdictions in the future. The company also revealed plans for a Phase 1b, First-In-Human study of its lead product candidate, PRP, in 2026, which will help define its therapeutic dose and explore its applications across multiple disease conditions. The patents represent a significant expansion of Propanc's intellectual property portfolio, especially as they detail the use of PRP for chronic diseases beyond cancer, such as fibrosis. The scientific results themselves have not yet been presented, as further studies are planned.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL694P6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2584629599","title":"Propanc Biopharma Q1 2025 EPS $(0.39) Up From $(35.97) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629599","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629599?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:54","pubTimestamp":1763387653,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Q1 2025 EPS $(0.39) Up From $(35.97) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48897108/propanc-biopharma-q1-2025-eps-0-39-up-from-35-97-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2584295346","title":"BRIEF-Propanc Biopharma Provides Corporate Update And Reports First Quarter 2025/26 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584295346","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584295346?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:52","pubTimestamp":1763387561,"startTime":"0","endTime":"0","summary":"BRIEF-Propanc Biopharma Provides Corporate Update And Reports First Quarter 2025/26 ResultsPropanc Biopharma Inc PPCB.O:PROPANC BIOPHARMA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2025/26 RE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUAB7GFQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2584629871","title":"Propanc Biopharma Reports Nasdaq Uplisting and $4 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629871","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629871?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:45","pubTimestamp":1763387113,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. announced its corporate update and financial results for the first quarter ended September 30, 2025. The company reported total current assets of $17 million and a reduction in total current liabilities by $2 million. Net cash from financing activities was $2.53 million, with quarter-end cash standing at $600,000. An initial $1 million tranche was received from a new $100 million private placement facility. Propanc completed a public offering of 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 million, and began trading on the Nasdaq Capital Market on August 15. The company is advancing its lead candidate, PRP, toward a Phase 1b clinical trial scheduled for 2026 and is progressing the Rec-PRP synthetic program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbX15SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","PPCB","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4585","LU2095319765.USD","BK4588","BK4139","NDAQ"],"gpt_icon":0},{"id":"2584629809","title":"Propanc Biopharma Inc Qtrly EPS $-0.39","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629809?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:45","pubTimestamp":1763387100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUAB7GFQB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2582682872","title":"Propanc Biopharma Secures Up to $100 Million in Private Placement from Hexstone Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582682872","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582682872?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:03","pubTimestamp":1762783411,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. has announced it has entered into a securities purchase agreement with Hexstone Capital LLC for a private placement of up to $100 million in convertible preferred stock. The company received an initial investment of $1 million upon closing, issuing 100 shares of newly designated Series C Convertible Preferred Stock. In addition, Propanc will issue 9,900 warrants to Hexstone, each allowing the purchase of one share of preferred stock at $10,000 per share, providing up to $99 million in potential additional funding. The funds are intended to support Propanc's digital asset acquisition strategy and accelerate its R&D pipeline, with a focus on advancing its PRP therapy to a First-In-Human study in the second half of 2026. Further details are available in the company's Form 8-K filing with the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbxzgmz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}